X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lapatinib (625) 625
oncology (592) 592
index medicus (586) 586
humans (585) 585
breast cancer (502) 502
female (493) 493
trastuzumab (473) 473
breast neoplasms - drug therapy (387) 387
her2 (251) 251
breast neoplasms - pathology (241) 241
cancer (238) 238
chemotherapy (238) 238
metastasis (224) 224
antineoplastic agents - therapeutic use (219) 219
receptor, erbb-2 - metabolism (198) 198
middle aged (192) 192
antineoplastic combined chemotherapy protocols - therapeutic use (191) 191
care and treatment (188) 188
lapatinib plus capecitabine (185) 185
capecitabine (173) 173
skin and connective tissue diseases (171) 171
adult (169) 169
aged (167) 167
breast neoplasms - metabolism (161) 161
open-label (156) 156
receptor, erbb-2 - antagonists & inhibitors (154) 154
brain metastases (153) 153
medicine & public health (150) 150
quinazolines - administration & dosage (148) 148
treatment outcome (145) 145
survival (142) 142
quinazolines - therapeutic use (136) 136
therapy (134) 134
phase-ii (129) 129
research (122) 122
tyrosine kinase inhibitor (120) 120
adjuvant chemotherapy (116) 116
drug therapy (116) 116
epidermal growth factor (116) 116
pertuzumab (116) 116
phase-ii trial (116) 116
antineoplastic agents (108) 108
monoclonal-antibody (108) 108
pharmacology & pharmacy (103) 103
hematology, oncology and palliative medicine (101) 101
brain neoplasms - secondary (97) 97
antimitotic agents (93) 93
metastatic breast cancer (93) 93
receptor, erbb-2 - genetics (93) 93
neoplasm metastasis (90) 90
disease-free survival (88) 88
growth-factor receptor (87) 87
1st-line treatment (85) 85
combination (85) 85
health aspects (85) 85
quinazolines - adverse effects (85) 85
analysis (84) 84
breast neoplasms - genetics (84) 84
animals (81) 81
antibodies, monoclonal, humanized - therapeutic use (80) 80
cancer therapies (80) 80
clinical trials (79) 79
protein kinase inhibitors - therapeutic use (79) 79
receptor (77) 77
antineoplastic combined chemotherapy protocols - adverse effects (76) 76
breast neoplasms - mortality (76) 76
neoplasms (76) 76
resistance (76) 76
efficacy (74) 74
nervous-system metastases (73) 73
tumors (72) 72
antineoplastic agents - pharmacology (71) 71
drug resistance, neoplasm (71) 71
antineoplastic agents - adverse effects (70) 70
antibodies, monoclonal, humanized (69) 69
prognosis (69) 69
deoxycytidine - analogs & derivatives (67) 67
erbb-2 protein (67) 67
cancer research (66) 66
metastatic breast-cancer (66) 66
cell line, tumor (65) 65
fluorouracil - analogs & derivatives (63) 63
metastases (63) 63
quinazolines - pharmacology (63) 63
trastuzumab emtansine (63) 63
breast-cancer (62) 62
expression (62) 62
plus (62) 62
review (61) 61
cell lung-cancer (60) 60
brain neoplasms - drug therapy (59) 59
deoxycytidine - administration & dosage (58) 58
molecular targeted therapy (58) 58
aged, 80 and over (57) 57
antibodies, monoclonal - therapeutic use (57) 57
clinical trials as topic (57) 57
trastuzumab resistance (56) 56
women (56) 56
development and progression (55) 55
fluorouracil - administration & dosage (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (823) 823
French (13) 13
Japanese (8) 8
German (4) 4
Polish (2) 2
Chinese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2008, Volume 112, Issue 3, pp. 533 - 543
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 12/2011, Volume 105, Issue 3, pp. 613 - 620
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2019, Volume 37, Issue 13, pp. 1044 - 1044
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2018, Volume 56, Issue 2, pp. 72 - 80
Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20-25% of cases of breast cancers, is highly aggressive.... 
Trastuzumab emtansine | Capecitabine | HER2-positive | breast cancer | Systematic review | T-DM1 | Lapatinib | Combination therapy | Trastuzumab | MULTICENTER | lapatinib | PHASE-II | systematic review | COMBINATION | SOCIETY | trastuzumab | capecitabine | trastuzumab emtansine | THERAPY | combination therapy | PHARMACOLOGY & PHARMACY | Breast cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 5, pp. 569 - 576
Abstract Introduction Human epidermal growth factor receptor 2 (HER2) amplification is present in a subgroup of gastroo-esophageal cancers (GCs). HER2... 
Hematology, Oncology and Palliative Medicine | Lapatinib | HER2 | Gastric cancer | EGFR | SURVIVAL | PLACEBO | OPEN-LABEL | KINASE INHIBITOR | CHEMOTHERAPY | PACLITAXEL | SUPPORTIVE CARE | ONCOLOGY | GW572016 | ADVANCED GASTRIC-CANCER | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Protein Kinase Inhibitors - adverse effects | Esophageal Neoplasms - pathology | Fluorouracil - administration & dosage | Time Factors | Esophageal Neoplasms - mortality | Adult | Female | Quinazolines - administration & dosage | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Signal Transduction | Deoxycytidine - administration & dosage | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Esophageal Neoplasms - enzymology | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Germany | Adenocarcinoma - mortality | Antimitotic agents | Epidermal growth factor | Clinical trials | Product development | Metastasis | Antineoplastic agents | Esophageal cancer
Journal Article
Oncology (Switzerland), ISSN 0030-2414, 07/2017, Volume 93, Issue 1, pp. 51 - 61
Journal Article
Journal Article
Journal Article
Surgical Neurology International, ISSN 2152-7806, 06/2019, Volume 10, p. 131
Background: Leptomeningeal metastases (LM) pose the most difficult form of cancer metastasis to treat and portend a poor prognosis. Standard treatment has yet... 
Journal Article
Journal of Chemotherapy, ISSN 1120-009X, 10/2014, Volume 26, Issue 5, pp. 300 - 305
Journal Article
Tumori, ISSN 0300-8916, 11/2013, Volume 99, Issue 6, pp. e278 - e281
We present the case of a 58-year-old woman with breast cancer metastasizing to the liver after adjuvant chemotherapy. A liver biopsy confirmed metastatic... 
HER2-positive metastatic breast cancer | Trastuzumab | Lapatinib | trastuzumab | lapatinib | ONCOLOGY
Journal Article
by Li, Q and Guan, XW and Chen, SS and Yi, ZB and Lan, B and Xing, PY and Fan, Y and Wang, JY and Luo, Y and Yuan, P and Cai, RG and Zhang, P and Zhong, DF and Zhang, YF and Zou, JJ and Zhu, XY and Ma, F and Xu, BH
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2019, Volume 25, Issue 17, pp. 5212 - 5220
Purpose: This phase I study assessed the safety, tolerability, MTD, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an... 
SURVIVAL | GROWTH-FACTOR RECEPTOR | EMTANSINE | AMPLIFICATION | ONCOLOGY | TYROSINE KINASE INHIBITOR | OPEN-LABEL | MUTATIONS | LAPATINIB PLUS CAPECITABINE | TRASTUZUMAB RESISTANCE | CONTRIBUTES
Journal Article